Results 51 to 60 of about 876 (115)
Analytical Science Advances, Volume 7, Issue 1, June 2026.ABSTRACT Sample preparation is a critical, yet often environmentally burdensome, step in analytical chemistry. While Green Sample Preparation principles aim to mitigate this impact, existing assessment tools such as AGREEprep offer room for improvement in the assessment process.
Fotouh R. Mansour +3 more
wiley +1 more source
VirusesOrthobunyavirus is the largest and most diverse genus in the family Peribunyaviridae. Orthobunyaviruses are widely distributed globally and pose threats to human and animal health.
Jingke Geng +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1650-1661, June 2026.AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland +48 more
wiley +1 more source
Scientific Reports, 2021 Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases.
Hany M. Dabbous +10 more
doaj +1 more source
Antiviral Resistance in Influenza: Clinical and Public Health Implications
Influenza and Other Respiratory Viruses, Volume 20, Issue 6, June 2026.ABSTRACT Timely antiviral treatment and prevention can diminish the morbidity and mortality caused by influenza seasonal, zoonotic, and pandemic infections. However, the emergence of antiviral resistance threatens the utility of available agents and sometimes contributes to poor clinical outcomes.
Jinghao Nicholas Ngiam +2 more
wiley +1 more source
Scientific Reports, 2022 Favipiravir has antiviral activity against influenza, West Nile virus, and yellow fever virus and against flaviviruses. The objective of this pilot study was to compare three arms: favipiravir; hydroxychloroquine; standard care (no specific SARS-CoV-2 ...
Manaf AlQahtani +12 more
doaj +1 more source
ChemMedChem, Volume 21, Issue 10, 27 May 2026.Development of a three‐step synthesis and replacement of the cycloheptyl moiety in cycloheptathiophene‐3‐carboxamide derivatives revealed how thiophene C‐5 substitutions modulate PA–PB1 inhibition, antiviral potency, and water solubility. The phenyl analog 9 delivered sub‐µM potency across multiple IV strains, while the methyl analog 5 achieved the ...
Tommaso Felicetti +8 more
wiley +1 more source
Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications
Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff +2 more
wiley +1 more source
Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir
Journal of Microbiology, Immunology and Infection, 2018 Background: T-705 (favipiravir) is a potent inhibitor of RNA-dependent RNA polymerases of influenza viruses and no favipiravir-resistant virus has been isolated.
Tohru Daikoku +6 more
doaj +1 more source
The mechanism of resistance to favipiravir in influenza [PDF]
Proceedings of the National Academy of Sciences, 2018 Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza virus infections. While emergence of resistance has been observed for many antiinfluenza drugs, to date, clinical trials and laboratory studies of favipiravir have not yielded resistant viruses.
Goldhill, Daniel H +6 more
openaire +3 more sources